Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population. Materials and Methods Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities. Results Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ! 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21. Conclusion R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ! 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.
Abstract
Purpose Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population. Materials and Methods Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities. Results Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ! 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21. Conclusion R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ! 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.
참고문헌 (22)
- Roman E, "Epidemiology of lymphomas", Histopathology, 58, pp.4~14 (2011)
- Pfreundschuh M, "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas : results of the NHL-B2 trial of the DSHNHL", Blood, 104, pp.634~641 (2004)
- Pfreundschuh M, "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis(normal LDH)aggressive lymphomas : results of the NHL-B1 trial of the DSHNHL", Blood, 104, pp.626~633 (2004)
- Coiffier B, "Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte", Blood, 116, pp.2040~2045 (2010)
- Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial(RICOVER-60)", Lancet Oncol, 9, pp.105~116 (2008)
- Pfreundschuh M, "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma : 6-year results of an open-label randomised study of the MabThera International Trial(MInT)Group", Lancet Oncol, 12, pp.1013~1022 (2011)
- Ziepert M, "Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era", J Clin Oncol, 28, pp.2373~2380 (2010)
- Delarue R, "Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma(the LNH03-6B study) : a randomised phase 3 trial", Lancet Oncol, 14, pp.525~533 (2013)
- Cunningham D, "Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3comparison of dose intensification with 14-day versus 21-day cycles", Lancet, 381, pp.1817~1826 (2013)
- Hans CP, "Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray", Blood, 103, pp.275~282 (2004)
- Cheson BD, "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group", J Clin Oncol, 17, pp.1244~ (1999)
- Cancer Therapy Evaluation Program, National Cancer Institute, "Common Terminology Criteria for Adverse Events" (2006), National Cancer Institute
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", N Engl J Med, 346, pp.235~242 (2002)
- Pfreundschuh M, "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial(MInT)Group", Lancet Oncol, 7, pp.379~391 (2006)
- Reyes F, "ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma", N Engl J Med, 352, pp.1197~1205 (2005)
- Tilly H, "Intensive conventional chemotherapy (ACVBP regimen)compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma", Blood, 102, pp.4284~4289 (2003)
- Recher C, "Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma(LNH03-2B) : an openlabel randomised phase 3 trial", Lancet, 378, pp.1858~1867 (2011)
- Tarella C, "Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support : a multicenter study by GITIL(Gruppo Italiano Terapie Innovative nei Linfomi)", Leukemia, 21, pp.1802~1811 (2007)
- Vitolo U, "Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis : a phase II multicenter study", Haematologica, 94, pp.1250~1258 (2009)
- Kurita D, "Dose-intensified CHOP with rituximab(R-Double-CHOP)followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma", Int J Hematol, 101, pp.585~593 (2015)
- Nowakowski GS, "Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma : a phase II study", J Clin Oncol, 33, pp.251~257 (2015)
- Younes A, "Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone(R-CHOP)for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma : a non-randomised, phase 1b study", Lancet Oncol, 15, pp.1019~1026 (2014)